Transdermal testosterone gel (Cellegy).
Cellegy is developing a drug delivery system designed to facilitate the transdermal and topical delivery of testosterone for the potential treatment of male hypogonadism (as Tostrex) and decreased sexual energy in post-menopausal women (asTostrelle) [218118], [314726], [351823]. Following phase III dinical trials of Tostrex for male hypogonadism, initiated in March 2000 [361133], an NDA submission for male hypogonadism was filed in June 2002, after a pre-NDA meeting with the FDA late in 2001 [453374]. By March 2002, phase II/III clinical studies in postmenopausal women were underway in the US [444857].
McGriff-Lee
Nayahmka J
NJ
University of the Sciences in Philadelphia, 600 South 43rd Street, Box 8 Philadelphia, PA 19104-4495, USA. n.mcgrif@usip.edu
D000279:Administration, Cutaneous; D000818:Animals; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D005782:Gels; D006801:Humans; D008777:Methyltestosterone / Q000008:administration & dosage* / Q000097:blood / Q000627:therapeutic use*; D012735:Sexual Dysfunction, Physiological / Q000097:blood / Q000188:drug therapy; D013678:Technology, Pharmaceutical / Q000379:methods*
D005782:Gels; D008777:Methyltestosterone